Is recombinant activated factor VII useful for intractable bleeding after cardiac surgery?

Area of Science:

• Cardiothoracic Surgery
• Hematology
• Pharmacology

Background:

• Intractable bleeding is a significant complication in cardiac surgery.
• Conventional hemostatic interventions may be insufficient in severe cases.
• Recombinant Activated Factor VII (Factor VIIa) is a potential therapeutic agent.

Purpose of the Study:

• To evaluate the efficacy and safety of Factor VIIa for intractable bleeding in cardiac surgery.
• To assess the risk of thrombotic complications associated with Factor VIIa use.
• To determine the optimal dosage and administration of Factor VIIa in this context.

Main Methods:

• Systematic review of 129 identified papers, focusing on 13 representing best evidence.
• Tabulation of data including patient groups, study types, outcomes, results, and weaknesses.
• Analysis of reported efficacy and complication rates from existing literature.

Main Results:

• Factor VIIa has demonstrated high efficacy (80-90%) in controlling intractable bleeding.
• Serious thrombotic complication rates are low, around 1-2% in cardiothoracic surgery.
• A single dose of 60-90 mcg/kg, potentially repeated, is effective.

Conclusions:

• Factor VIIa is a recommended treatment for intractable bleeding post-cardiac surgery refractory to conventional hemostasis.
• Its proven efficacy and low complication rates support its use in this critical setting.
• Experience from over 400,000 worldwide uses, primarily in hemophiliacs, supports its safety profile.